Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
54868-5667-03 54868-5667 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Sept. 8, 2006 No Longer Used
00093-8229-28 00093-8229 Sunitinib Malate Sunitinib Malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-8231-28 00093-8231 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-8224-28 00093-8224 Sunitinib Malate Sunitinib Malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-8199-28 00093-8199 Sunitinib Malate Sunitinib Malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-7662-56 00093-7662 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Dec. 8, 2021 In Use
51862-0682-00 51862-0682 TAMOXIFEN CITRATE SOLTAMOX 20.0 mg/10mL Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 6, 2021 In Use
51862-0682-01 51862-0682 TAMOXIFEN CITRATE SOLTAMOX 20.0 mg/10mL Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral June 18, 2021 In Use
63739-0143-10 63739-0143 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 14, 2021 In Use
68788-8112-03 68788-8112 Medroxyprogesterone Acetate Medroxyprogesterone Acetate 5.0 mg/1 Hormonal Therapy Progestin Oral Dec. 6, 2021 In Use
70771-1626-08 70771-1626 Fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
70710-1688-08 70710-1688 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
75834-0132-05 75834-0132 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0132-14 75834-0132 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0142-05 75834-0142 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0142-14 75834-0142 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0143-05 75834-0143 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0143-14 75834-0143 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0144-05 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0144-14 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0145-05 75834-0145 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0145-14 75834-0145 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
80425-0072-01 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-02 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-03 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-04 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-05 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
42291-0321-01 42291-0321 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral July 23, 2013 In Use
42291-0505-01 42291-0505 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 5, 2020 In Use
42388-0013-14 42388-0013 Cabozantinib COMETRIQ 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
43975-0256-05 43975-0256 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
43975-0256-14 43975-0256 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
44087-3535-01 44087-3535 Avelumab Bavencio 20.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 23, 2017 In Use
50742-0404-01 50742-0404 Topotecan Topotecan 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 7, 2016 In Use
50742-0423-10 50742-0423 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0420-01 50742-0420 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0427-05 50742-0427 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0481-20 50742-0481 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0512-20 50742-0512 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sept. 27, 2018 In Use
50742-0525-07 50742-0525 arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Jan. 27, 2021 In Use
54879-0021-01 54879-0021 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
54879-0022-01 54879-0022 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
72187-0401-01 72187-0401 Tagraxofusp Elzonris 1000.0 ug/mL Immunotherapy Fusion Protein IL3/ CD123 Intravenous Jan. 18, 2019 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
50242-0245-01 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0245-86 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
50242-0260-01 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0260-86 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sept. 20, 2021 In Use
57277-0107-45 57277-0107 carboplatin Injection Carboplatin 450.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
59148-0070-91 59148-0070 Busulfan Busulfex 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Feb. 4, 1999 In Use
61126-0004-01 61126-0004 Cisplatin Platinol-AQ 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 In Use
61703-0303-46 61703-0303 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 31, 1990 In Use
62756-0826-40 62756-0826 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 20, 2012 In Use
62756-0827-40 62756-0827 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 20, 2012 In Use
63304-0158-01 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0158-30 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0962-01 63304-0962 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0962-30 63304-0962 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63323-0637-10 63323-0637 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Aug. 31, 2018 In Use
63539-0197-90 63539-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 1, 2019 In Use
63759-0003-01 63759-0003 azacitidine for Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Dec. 5, 2016 In Use
63759-3000-01 63759-3000 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 31, 2016 In Use
63759-3001-01 63759-3001 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 31, 2016 In Use
64842-1020-01 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 7, 2015 In Use
64842-1020-02 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 11, 2015 In Use
64842-1020-03 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 21, 2015 In Use
64842-1025-01 64842-1025 Trifluridine and Tipiracil Lonsurf 6.14 mg/1, 15.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 7, 2015 In Use
64842-1025-02 64842-1025 Trifluridine and Tipiracil Lonsurf 6.14 mg/1, 15.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 11, 2015 In Use
64842-1025-03 64842-1025 Trifluridine and Tipiracil Lonsurf 6.14 mg/1, 15.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 21, 2015 In Use
66336-0338-21 66336-0338 METHOTREXATE Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
66336-0338-30 66336-0338 METHOTREXATE Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
66758-0051-01 66758-0051 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 25, 2011 In Use
66758-0051-03 66758-0051 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 25, 2011 In Use
66758-0051-05 66758-0051 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 25, 2011 In Use
66828-0030-01 66828-0030 Imatinib Mesylate Gleevec 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 15, 2001 In Use
53217-0374-10 53217-0374 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 17, 2018 In Use
67877-0537-07 67877-0537 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0537-14 67877-0537 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0538-07 67877-0538 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0538-14 67877-0538 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0539-07 67877-0539 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0539-14 67877-0539 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0540-07 67877-0540 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0540-14 67877-0540 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0541-07 67877-0541 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0541-14 67877-0541 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0542-07 67877-0542 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
68151-1305-00 68151-1305 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 No Longer Used
68382-0775-01 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-05 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-10 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-16 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-60 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-77 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
69097-0313-37 69097-0313 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0314-42 69097-0314 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0805-40 69097-0805 Azacitidine Azacitidine For 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 26, 2019 In Use

Found 10,000 results in 7 millisecondsExport these results